Latest Breaking News On - Mortality worldwide - Page 17 : comparemela.com

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA combination reduced the risk of disease progression or death by 76% vs. abiraterone alone First PARP inhibitor approved in combination with a novel hormonal agent underscores clinically. | June 1, 2023

United kingdomNorth carolinaUnited statesComunidad autonoma de catalunaDave fredricksonEliav barrAndrew armstrongData monitoring committeeMerck coHead of global clinical developmentEuropean unionResearch laboratoriesDuke cancer instituteOncology group trialsMerck co incExecutive vice president

Takeda and HUTCHMED Announce New Drug Application NDA for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Takeda TSE4502NYSETAK and HUTCHMED China Limited NasdaqAIMHCM HKEX13 HUTCHMED today announced that the U.S. Food and Drug Administration FDA has granted priority review of the New Drug Application NDA for fruquintinib a highly selective and potent inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer CRC.

United kingdomHong kongUnited statesAl qahirahJun saitoMark leeSara noonanMichael shiAhcene djaballahJemma nashZhou yiBen atwell alex shawGastroenterol hepatolAnnie chengAwny farajallahExchange commission

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongAl qahirahUnited kingdomJemma nashPanmure gordonMichael shiMark leeBen atwell alex shawZhou yiAwny farajallahJun saitoAnnie chengAhcene djaballahGastroenterol hepatolSara noonan

Takeda Pharmaceutical (TAK) and HUTCHMED (HCM) Announce New Drug Application (NDA) for Fruquintinib

Takeda Pharmaceutical (TAK) and HUTCHMED (HCM) Announce New Drug Application (NDA) for Fruquintinib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Al qahirahUnited kingdomUnited statesHong kongJun saitoSara noonanAhcene djaballahGastroenterol hepatolBen atwell alex shawJemma nashAnnie chengAwny farajallahPanmure gordonZhou yiMark leeMichael shi

Takeda Pharmaceutical Company Limited: Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023 NDA Includes Results From the Phase 3 FRESCO-2 and FRESCO Clinical Trials Takeda (TSE:4502/NYSE:TAK) and HUTCHMED

United kingdomAl qahirahUnited statesHong kongAnnie chengMichael shiJemma nashAsia zhou yiPanmure gordonJun saitoGewinn nurAwny farajallahMark leeGastroenterol hepatolAhcene djaballahSara noonan